国产坎地沙坦酯与厄贝沙坦治疗原发性轻中度高血压疗效比较

目的探讨国产坎地沙坦酯对原发性轻中度高血压患者的疗效和安全性。方法60例原发性轻中度高血压患者,随机分为坎地沙坦酯和厄贝沙坦组,每组30例,采用双盲双模拟平行对照研究。经过2周的安慰剂清洗期后两组患者分别接受坎地沙坦酯片一日8mg或厄贝沙坦片一日150mg。2周后如果达到预期降压效果,则继续原剂量服药至4周末。如降压效果不理想,加量(坎地沙坦酯一日12mg或厄贝沙坦一日225mg)继续服药2周。观察所有入选患者4周内的血压、不良反应和生化指标变化。结果治疗结束时坎地沙坦酯组收缩压下降15.1%,舒张压下降12.2%;厄贝沙坦组收缩压下降12.6%,舒张压下降9.2%。两组相比无显著差异。两组均未见严重不良反应。结论国产坎地沙坦酯为治疗原发性轻中度高血压安全且有效的药物。

Comparison of the Effects of Candesartan Cilexetil and Irbesartan on Mild and Moderate Essential Hypertension

Objective To evaluate the efficacy and safety of candesartan cilexetil in the treatment of patients with mild- to-moderate essential hypertension. Methods This was a double-blind, double-modelling, randomised, parallel group study. After a placebo run-in period of 2 weeks, 60 patients with essential hypertension were administered candesartan cilexetil 8mg(n=30)or irbesartan 150mg(n=30)once daily for 2 weeks. If the blood pressure was still over standard, the dosages of candesartan cilexetil or irbesartan would be increased to 12mg or 225mg once daily from the 3th week till the end of 4th week. Blood pressure and heart rate were determined, and adverse drug reactions were observed every 2 weeks. Before and after the trial, laboratory tests were performed. Result The systolic blood pressure(SBP) and diastolic blood pressure (DBP) decreased significantly after the treatment for 4 weeks in both groups. The SBP and DBP were decreased by 15.1% and 12.2% in candesartan cilexetil group, and by 12.6% and 9.2% in irbesartan group.There was no significant difference between two groups. There were no serious adverse drug reactions in both groups. Conclusion Candesartan cilexetil can be used in the treatment of patients with mild and moderate essential hypertension effectively and safely.